Hi, everybody. I’m Chris Gibson, Co-Founder and CEO of Recursion, and I'm so delighted you've joined us today for our Q1 2024 Earnings Call -- L(earnings) Call, as we call it. And I want to run through some of the exciting updates from the company over the last quarter as we move forward to achieve our mission of decoding biology to radically improve lives. And so with that, of course, some disclaimers. And Recursion, I think, is uniquely positioned to hit the TechBio escape velocity. And what I mean by that is I think we have pretty uniquely put together the pipeline, the platform, and the people that are giving us the opportunity over the coming quarters and years to really start to demonstrate a shift in the pace, the scale and hopefully, also the probability of success of drug discovery and development. And we're just delighted to be in this position to be helping to lead TechBio because we feel so confident about what the future looks like. We feel that the future of TechBio is the inevitable future of biotech. And we are delighted to be leading that and so thankful that all of you are supporting us. So, with that, I'm going to go ahead and dive in to a little bit of what we're working on, and I'm going to start with the pipeline. And the pipeline, in particular, I think, is very exciting because we have an opportunity to start to demonstrate catalysts on a roughly quarterly cadence. These catalysts are going to start in Q3 with our first Phase 2 readout and then again, we're going to start to be able to demonstrate Phase 2 POC readouts on a quarterly cadence. We'll kick off with REC-994, the SYCAMORE trial and cerebral cavernous malformation. This…